TilrayTLRY
About: Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Employees: 2,650
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
12% more capital invested
Capital invested by funds: $145M [Q2] → $162M (+$17M) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 87
0.06% less ownership
Funds ownership: 10.55% [Q2] → 10.49% (-0.06%) [Q3]
5% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 37
2% less funds holding
Funds holding: 353 [Q2] → 345 (-8) [Q3]
10% less call options, than puts
Call options by funds: $21.2M | Put options by funds: $23.6M
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for TLRY.
Financial journalist opinion
Based on 24 articles about TLRY published over the past 30 days